TECHHealthcare · BiotechnologyThe 14 Wall Street analysts covering Bio-Techne Corp. hold a median 12-month price target of $73 — +1.2% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 88 of 100 as at 1 Aug 2026 — inside the top quartile. Here, the model and the Street point the same way.
Consensus tells you what everyone already believes. The model scores Bio-Techne Corp. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Issuance (94): The share count has been shrinking and the company is not leaning on new borrowing.
Revisions (46): Analysts have, on balance, been cutting their forecasts.
Size (15): Larger than most of the companies we track — more scrutinised, less often mispriced.
The rank is the raw material. Whether the rules would actually own Bio-Techne Corp. — and when they’d sell — is the membership.
The bullish and bearish analyst opinions on TECH, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
The green dot is the last close — the median target sits +1.2% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 9 July 2026 | RBC Capital | Downgrade | Sector Perform | $62 → $73 |
| 30 June 2026 | Benchmark | Downgrade | Hold | — |
| 30 June 2026 | TD Cowen | Downgrade | Hold | — |
| 29 June 2026 | Citigroup | Downgrade | Neutral | — |
| 26 June 2026 | Baird | Maintains | Neutral | — |
| 26 June 2026 | Stephens & Co. | Downgrade | Equal-Weight | — |
| 26 June 2026 | William Blair | Downgrade | Market Perform | — |
| 11 June 2026 | Piper Sandler | Initiates | Neutral | — |
| 15 May 2026 | RBC Capital | Reinstates | Outperform | $62 |
| 7 May 2026 | Citigroup | Maintains | Buy | — |
| 7 May 2026 | Evercore ISI Group | Maintains | In-Line | — |
| 7 May 2026 | Wells Fargo | Maintains | Overweight | — |
| 6 Apr 2026 | Evercore ISI Group | Maintains | In-Line | — |
| 6 Feb 2026 | Wells Fargo | Maintains | Overweight | — |
| 5 Feb 2026 | Citigroup | Maintains | Buy | — |
| 5 Feb 2026 | Evercore ISI Group | Maintains | In-Line | — |
| 5 Feb 2026 | Stifel | Maintains | Hold | — |
| 5 Feb 2026 | TD Cowen | Maintains | Buy | — |
| 5 Feb 2026 | UBS | Maintains | Buy | — |
| 5 Jan 2026 | Evercore ISI Group | Downgrade | In-Line | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 7% of US stocks
Cheaper than 15% of US stocks
Cheaper than 19% of US stocks
Cheaper than 9% of US stocks
Higher than 27% of US stocks
Higher than 88% of US stocks
Higher than 81% of US stocks
Higher than 85% of US stocks
Higher than 68% of US stocks
Higher than 54% of US stocks
Higher than 87% of US stocks
Higher than 8% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The nearest names by industry and size, scored by the same model — like for like.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. TECH appears on the weeks it earns a place.
The Madison Mid Cap Fund reported that Bio-Techne was one of the top five contributors to portfolio performance in the second quarter of 2026.
Why it matters — The mention of Bio-Techne as a top contributor signals strong recent performance of the stock from the perspective of an active fund manager.
Conestoga SMid Cap Composite's Q2 2026 portfolio review noted growth at West Pharmaceuticals and Tyler Technologies, as well as attraction to Knowles Corporation based on organic growth and margin expansion.
Why it matters — The review discusses companies in the broader life-sciences and technology supply chain, offering context on trends that could influence Bio-Techne's market environment.
Bio-Techne (TECH) is approaching its fiscal fourth-quarter earnings release, with expectations of flat revenues, a decline in EPS, and attention on its $11.3 billion acquisition deal.
Why it matters — A TECH watcher would care because the earnings results and the progress of the acquisition deal could signal the company's near-term financial health and strategic direction.
The 14 Wall Street analysts covering Bio-Techne Corp. have a median 12-month price target of $73, with estimates ranging from $50 to $73. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 14 analysts covering Bio-Techne Corp., 2 rate it a Buy, 12 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Bio-Techne Corp. 88 out of 100 across roughly 4,600 US stocks as at 1 Aug 2026. None of this is personal advice — it does not consider your circumstances.
As at 1 Aug 2026, Bio-Techne Corp. ranks 88 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Issuance (94 of 100).
No one can know that. What the data says: the median 12-month target from 14 analysts implies +1.2% from the last close, and Ticker Nerd's factor model ranks Bio-Techne Corp. 88 out of 100 as at 1 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Bio-Techne Corp. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for TECH are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $50 to $73 over the next 12 months.
Bio-Techne Corp. returned +32.2% over the 12 months to 3 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.
Bio-Techne Corporation is a global life sciences company that develops, manufactures, and supplies specialized tools for research and clinical diagnostics. The company focuses on high-quality reagents, analytical instruments, and precision diagnostic products used across pharmaceutical, biotechnology, academic, and clinical laboratory settings.
The most recent item we track (Seeking Alpha, 31 July 2026): "Madison Mid Cap Fund Q2 2026 Portfolio Activity". The Madison Mid Cap Fund reported that Bio-Techne was one of the top five contributors to portfolio performance in the second quarter of 2026.
Bio-Techne Corporation is a global life sciences company that develops, manufactures, and supplies specialized tools for research and clinical diagnostics. The company focuses on high-quality reagents, analytical instruments, and precision diagnostic products used across pharmaceutical, biotechnology, academic, and clinical laboratory settings. Through its protein sciences activities, Bio-Techne provides antibodies, bioactive proteins, assays, and related instruments that support investigations into cellular pathways, disease mechanisms, and therapeutic targets. Its diagnostics and spatial biology offerings include diagnostic reagents, molecular diagnostic solutions, and advanced platforms for visualizing and quantifying biomolecules in tissues, supporting pathology and translational research. Bio-Techne serves a diversified customer base involved in drug discovery, basic and applied research, and high-complexity diagnostic testing, helping ensure reproducible and consistent experimental results. Incorporated in 1981 and headquartered in Minneapolis, Minnesota, Bio-Techne today plays a significant role in the global life sciences infrastructure by providing critical consumables and instruments that are embedded in laboratory workflows worldwide.
CEO Mr. Kim Kelderman · 3,100 employees · United States · https://www.bio-techne.com